


Title: Immunotoxins, Comprising an Internalizing Antibody, Director Against Malignant and Normal Conventor(s): David M. Goldenberg DOCKET NO.: 018733-1058

PCT/US98/08983

1/9




Title: Immunotoxins, Comprising an Internalizing Antibody, Directed Against Malignant and Normal Cells Inventor(s): David M. Goldenberg DOCKET NO.: 018733-1058

'WO 98/50435







Title: Immunotoxins, Comprising an Internalizing Antibody, Directed Against Malignant and Normal Cells Inventor(s): David M. Goldenberg WO 98/50435 PCT/US/98/08983 DOCKET NO.: 018733-1058 3/9 LL2-ONC LL2-EDN LL1-ONC CA-46 CA-46 CA-46 LL1-EDN LL2-Onc LL2-EDN CA-46 Daudi Daudi 100 Protein Synthesis (% control) 75 · 50· 25 0.001 0.01 0.1 100 Concentration , (nM)

Fi/g. 3


**\$UBSTITUTE SHEET (RULE 26)** 

Title: Immunotoxins, Comprising an Internalizing Antibody, Directed Against Malignant and Normal Cells Inventor(s): David M. Goldenberg DOCKET NO.: 018733-1058


PCT/US98/08983

4/9

## The Effect of LL2-Onc vs LL2-hPanc on Daudi Lymphoma cells








DOCKET NO.: 018733-1058

PCT/US/98/08983





Title: Immunotoxins, Comprising an Internalizing Antibody, Direct Against Malignant and Normal Inventor(s): David M. Goldenberg PC/T/US98/08983 WO 98/50435 DOCKET NO.: 018733-1058 7/9 AIPT Daudii.v. in SCID mice, 120996 100 80 70 % Animal non-paralyzed 60 50 40 30 -D-PBS — m-LL2 (500 ug/an) 20 -LL2-ONC (500 ug/an) 10 10 40 50 20 Days Fig. 7 SUBSTITUTE SHEET (RULE 26)

Title: Immunotoxins, Comprising an Internalizing Antibody, Directed

Title. Immunotoxins, Comprising an Internalizing Antibody, Directed Against Malignant and Normal Ills Inventor(s): David M. Goldenberg DOCKET NO.: 018733-1058

PCT/US98/08983/

9/9

Toxicity of LL2-Onc vs Onc or IT-dgRTA to Mice

